Table 1:
Patients’ Demographic and Clinical Characteristics
| Patients’ Demographic and Clinical Characteristics | N = 110 |
|---|---|
| Male, (%) | 59 (54) |
| Age at diagnosis, median (IQR), y | 23 (18–30) |
| Age at infliximab initiation, median (IQR), y | 25 (32–43) |
| Disease duration: median (IQR), y | 8 (3–16) |
| Time from start of infliximab to first TDM: median (IQR), months | 15.3 (6.9–42.6) |
| Behavior: B1 / B2 / B3a, (%) | 54 (49) / 18 (16) / 38 (35) |
| Location: L1 / L2 / L3 / L4a, (%), n = 109 | 20 (18) / 25 (23) / 59 (54) / 5 (5) |
| Anti-TNF naïve, (%) | 102 (93) |
| Smoking at first TDM, (%) | 19 (17) |
| Infliximab dosing other than 5mg/Kg every 8 weeks at first TDM, (%) | 47 (43) |
| Concomitant IMM at first TDM, (%) | 28 (26) |
| BMI at first TDM, median (IQR), Kg/m2, n = 80 | 24.8 (21.6–29.1) |
| Perianal fistulizing CD, (%) | 43 (39) |
| Prior ileocolonic resection, (%) | 20 (18) |
| CRP at first TDM, median (IQR), mg/L, n = 49 | 2.5 (0.7–6.6) |
| HMSA at first TDM, (%) | 72 (66) |
| Infliximab TC at first TDM, median (IQR), μg/mL | 6.8 (3.2–12.2) |
| ATI at first TDM, (%) | 9 (8) |
aaccording to Montreal classification; bthiopurines
y: years